Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing
PALO ALTO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq:SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that a recent market research study among rheumatologists revealed a high degree of interest in Gloperba® as a liquid colchicine formulation designed for precision dosing.5 Specifically, clinicians using colchicine for prophylaxis of gout flares in adults indicated a strong likelihood to use Gloperba® instead of tablets/capsules in certain at-risk patient populations who have a clinical need for lowered precision dosing to mitigate the risk of colchicine toxicity. Notably, the American College of Rheumatology (ACR) guidelines also reflect this need.6 Scilex is currently in discussions with the U.S. Food and Drug Administration (FDA) regarding the dosing recommendations for these patient populations.
Related news for (SCLX)
- Proof of Human, Promise of Profit
- MoBot’s Stock Market Highlights – 03/03/25 04:00 PM
- Today’s Top Performers: MoBot’s Market Review 03/03/25 03:00 PM
- Denali Capital Acquisition Corp and Scilex Holding’s Semnur Pharmaceuticals Sign LOI for Proposed Business Combination
- Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024